These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12242147)

  • 1. Tumor-mediated apoptosis of cancer-specific T lymphocytes--reversing the "kiss of death"?
    Trapani JA
    Cancer Cell; 2002 Sep; 2(3):169-71. PubMed ID: 12242147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment abnormalities and lymphomagenesis: Immunological aspects.
    Taylor JG; Gribben JG
    Semin Cancer Biol; 2015 Oct; 34():36-45. PubMed ID: 26232774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Elimination of autologous cytotoxicity at the level of nonspecific adhesion].
    Cheknev SB
    Vestn Ross Akad Med Nauk; 2000; (10):51-5. PubMed ID: 11247127
    [No Abstract]   [Full Text] [Related]  

  • 4. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
    Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
    J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
    Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
    Front Immunol; 2018; 9():1301. PubMed ID: 29930558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.
    Martinez-Lostao L; de Miguel D; Al-Wasaby S; Gallego-Lleyda A; Anel A
    Immunotherapy; 2015; 7(8):883-2. PubMed ID: 26314314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of immune escape of cancer and its regulation.
    Morita R; Hirohashi Y; Torigoe T
    Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
    [No Abstract]   [Full Text] [Related]  

  • 9. Complex role of γδ T-cell-derived cytokines and growth factors in cancer.
    Ramstead AG; Jutila MA
    J Interferon Cytokine Res; 2012 Dec; 32(12):563-9. PubMed ID: 23078623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.
    Zhang H; Li Y; Liu X; Liang Z; Yan M; Liu Q; Chen A; Bao Y; Zhou C; Li S; Yee C; Li Y
    Immunology; 2018 Oct; 155(2):238-250. PubMed ID: 29791021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
    Rich RF; Green WR
    J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
    Bakker AB; Phillips JH; Figdor CG; Lanier LL
    J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic activity of T cells expressing different T-cell receptor variable gene products in the intestinal mucosa.
    Baca-Estrada ME; Croitoru K
    Adv Exp Med Biol; 1995; 371A():151-2. PubMed ID: 8525895
    [No Abstract]   [Full Text] [Related]  

  • 16. Protect the killer: CTLs need defenses against the tumor.
    Freeman GJ; Sharpe AH; Kuchroo VK
    Nat Med; 2002 Aug; 8(8):787-9. PubMed ID: 12152031
    [No Abstract]   [Full Text] [Related]  

  • 17. Perforin expression can define CD8 positive lymphocyte subsets in pigs allowing phenotypic and functional analysis of natural killer, cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells.
    Denyer MS; Wileman TE; Stirling CM; Zuber B; Takamatsu HH
    Vet Immunol Immunopathol; 2006 Apr; 110(3-4):279-92. PubMed ID: 16325923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models.
    Liu JQ; Bai XF
    Curr Mol Med; 2008 Feb; 8(1):68-75. PubMed ID: 18289015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment and immune escape.
    Ferrone S; Whiteside TL
    Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.